CTLA4 and neoplasm: Immune checkpoint inhibitor therapy is a form of cancer treatment that blocks receptors and their ligands, such as PD-1, PD-L1, and CTLA-4, which regulate immune responses, thereby enhancing the ability of T cells to recognize and attack tumor cells.